Current therapeutic options for managing familial Mediterranean fever

Batu E. D., Arici Z. S., BİLGİNER Y., ÖZEN S.

EXPERT OPINION ON ORPHAN DRUGS, vol.3, no.9, pp.1063-1073, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 3 Issue: 9
  • Publication Date: 2015
  • Doi Number: 10.1517/21678707.2015.1073149
  • Journal Name: EXPERT OPINION ON ORPHAN DRUGS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1063-1073
  • Keywords: amyloidosis, anti-IL-1, colchicine, familial Mediterranean fever, treatment, COLCHICINE-RESISTANT, SUBCLINICAL INFLAMMATION, RECEIVING COLCHICINE, INTERFERON-ALPHA, PATIENT, CHILDREN, ANAKINRA, AMYLOIDOSIS, INFLIXIMAB, EFFICACY
  • Hacettepe University Affiliated: Yes

Abstract

Introduction: Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disease characterized by recurrent attacks of fever and serositis. Although colchicine prevents the recurrence of FMF attacks and the development of secondary amyloidosis, the major long-term complication of FMF in most of the patients; 5 - 10% of patients may have inadequate symptom control despite good adherence to colchicine in maximally tolerated doses.